Mendus published its second-quarter report on Friday, August 23.
In an interview with Antti, CEO Erik Manting summarizes what happened during the second quarter, highlights the key achievements of the CADENCE trial, and discusses the new study for the drug Ilixadencel.
Topics:
00:00 Start
00:14 What has happened during Q2
04:58 The CADENCE trial
08:04 Main milestones in CADENCE
09:36 Immune activation in AML patients - What have you learned?
12:19 New trial with Ilixadencel
15:16 Timeline for the trial
15:54 Building readiness in AML